Hypokalemia is a known risk factor for sudden cardiac death. Proarrhythmic effects of hypokalemia have been related to reduced repolarization reserve as a result of direct suppression of multiple K + currents and inhibition of the Na-K pump, causing increases in intracellular Ca 2+ (Ca i ). We hypothesized that Ca i overload in this setting may activate apamin-sensitive small-conductance calcium-activated K + current (I KAS ), attenuating the reduction in repolarization reserve and protecting against arrhythmias. In the present study, we documented that I KAS was indeed upregulated during hypokalemia, especially at sites of late activation during ventricular pacing, which exacerbated Ca overload. Apamin, a specific I KAS blocker, increased ventricular vulnerability to fibrillation. These findings support the notion that I KAS may act as a rescue current to counteract excessive reduction in repolarization reserve during hypokalemia, reducing the risk of arrhythmias. In addition to hypokalemia, other conditions associated with reduced repolarization reserve and abnormal Ca handling such as heart failure and myocardial infarction have also been shown to increase I KAS . Blocking I KAS by drugs or foods might remove this rescue mechanism and make the patients more vulnerable to ventricular arrhythmias and sudden death, especially in the setting of chronic right ventricular pacing or frequent premature ventricular contractions. We conclude that I KAS may be an important rescue current that helps to maintain repolarization reserve in diseased conditions and hypokalemia. These findings may be important for understanding drug safety and the detrimental effects of ventricular pacing and frequent premature ventricular contractions. See p 1377.
Intramural Ventricular Septal Defect Is a Distinct Clinical Entity Associated With Postoperative Morbidity in Children After Repair of Conotruncal Anomalies
Intramural ventricular septal defect (VSD) is a type of residual defect that can occur after biventricular repair of conotruncal defects such as tetralogy of Fallot, transposition of the great arteries, and double-outlet right ventricle. The defect was first described in a case series of 8 patients >20 years ago. In this previous series, intramural VSDs were associated with considerable morbidity and mortality, including multiple unsuccessful reoperations and 3 deaths. Since that time, intramural VSDs have not been well studied or characterized. To the best of our knowledge, this study represents the first comprehensive evaluation of the prevalence, risk factors, and outcomes of residual intramural VSDs. We evaluated 442 children with repaired conotruncal defects and found that the presence of an intramural VSD, as identified by postoperative transthoracic echocardiogram, was associated with early mortality, extracorporeal membrane oxygenation use, and need for subsequent catheter or surgical VSD closure. The presence of an intramural VSD was also associated with a longer postoperative length of stay. Our study offers compelling evidence that the residual intramural VSD is a distinct clinical entity that is associated with worse postoperative outcome compared with other types of residual VSD. Recognition of this lesion may identify a population of children at risk for postoperative events who may benefit from close follow-up. Additionally, given the morbidity of intramural VSDs, increased awareness to prevent these lesions and to identify them early may improve overall outcome for patients with conotruncal anomalies who undergo biventricular repair. See p 1387.
Anti-Inflammatory Treatment With Colchicine in Acute Myocardial Infarction: A Pilot Study
In this study, a short course of colchicine treatment or placebo was administered to 151 patients with ST-segment-elevation acute myocardial infarction treated with primary percutaneous coronary intervention. Colchicine was started in the catheterization laboratory and was continued for 5 days. The primary end point was the area under the creatine kinase-myocardial brain fraction curve over the first 72 hours of hospitalization and, in a subset of 60 patients, infarct size was also assessed with cardiac MRI with late gadolinium enhancement 6 to 9 days after the index myocardial infarction. Both biomarkerand MRI-late gadolinium enhancement-defined infarct size was smaller in patients of the active treatment group. Infarct size was positively associated with markers of inflammation (neutrophil count and C-reactive protein), and colchicine treatment was correlated with lower levels of these markers. The findings suggest a role for anti-inflammatory treatment in the peri-infarct period. Although the study was not powered to assess clinical outcomes, the surrogate outcome measures that were used are well-established correlates of prognosis and clinical events. Still, for any firm recommendations for colchicine treatment in patients with acute myocardial infarction to be made, a larger study with clinical end points would be needed. See p 1395.
Clinical Effectiveness of Statin Therapy After Ischemic Stroke: Primary Results From the Statin Therapeutic Area of the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study
Patients with ischemic stroke are at high risk for both recurrent stroke and cardiovascular events. Although clinical trials have demonstrated that statin therapy reduces the risk of cardiovascular events after stroke, real-life clinical safety and effectiveness data are lacking, particularly for older stroke patients. In our study of a population of older patients who were not taking statins at the time of admission for ischemic stroke, more than one quarter were not discharged on statin therapy, and only 31% of statin-treated patients received a high-intensity statin. As new guidelines recommending intensive statins for all patients with a history of atherosclerotic cardiovascular disease are adopted, these data provide Volume 132 ◼ Number 15 ◼ October 13, 2015
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information on guideline adherence that may inform future quality-improvement efforts. We found that discharge statin receipt was associated with a lower risk of major adverse cardiovascular events and mortality across all major subgroups, an important finding for real-world stoke patients who may be underrepresented in clinical trials. We found similar benefits for each of our primary end points for both low/medium-and high-intensity statin doses. These results were robust to adjustment for patient characteristics, event characteristics, and receipt of other discharge medications. In the 2-year period after discharge, statin use was also associated with an additional 28 days of home time, a patient-centered metric representing days alive and out of the hospital or a skilled nursing facility. Because home time was selected as a high-priority outcome by our patient coinvestigators, these data can be used to support shared, patient-centered decision making for statin use after stroke. See p 1404.
Coordinated Membrane Ballooning and Procoagulant Spreading in Human Platelets
Platelets play a central role in hemostasis and arterial thrombosis, in particular, being the critical cells that cause arterial blockage in coronary artery disease. They rapidly form platelet aggregates at sites of blood vessel damage, such as occurs at sites of atherosclerotic plaques, and these aggregates are stabilized by the local production of thrombin and the generation of a fibrin clot. Platelets coordinate the localized clotting process by exposing phosphatidylserine on their cell surface, allowing the recruitment of the tenase and prothrombinase complexes to form a procoagulant surface. The procoagulant activity therefore depends on the surface area of membrane with exposed phosphatidylserine. We showed here that this is enhanced substantially by the formation of balloon structures, with subsequent procoagulant spreading of platelets over the adherent surface. Bleeding defects may thus be attributable to aberrant procoagulant membrane dynamics as exemplified by Scott patients. Furthermore, platelet membrane ballooning and procoagulant spreading is driven by a coordinated system of salt and water entry, which may be modified pharmacologically. Acetazolamide, used clinically for several indications, has actions that include the blockade of water entry into cells. We showed that acetazolamide not only substantially impaired ballooning and thrombin generation in vitro, but also markedly reduced thrombus formation in an in vivo model of thrombosis in mice. Drugs that modify water entry into platelets may therefore represent novel antithrombotic therapies for the management of coronary artery disease and the prevention of stroke. Furthermore, we provide added rationale for monitoring patient bleeding risk when acetazolamide is coadministered with anticoagulants. See p 1414.
